COVID-19 Management: What We Need to Know?

Manikandan Dhanushkodi; Padmaj Kulkarni

doi:10.4103/ijmpo.ijmpo_192_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 441-445
DOI: 10.4103/ijmpo.ijmpo_192_20

Editorial Commentary

COVID-19 Management: What We Need to Know?

Manikandan Dhanushkodi

¹Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

,

Padmaj Kulkarni

²Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India

› Author Affiliations

Abstract

Full Text

References

References
1 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177-9
2 Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC. et al. Diagnosing COVID-19: The disease and tools for detection. ACS Nano 2020; 14: 3822-35
3 COVID-19 Indian Council of Medical Research Government of India. https://icmr.nic.in/content/covid-19 Available from: [Last accessed on 2020 Apr 15]
4 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 323: 1824-36
5 Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020 NEJMoa2007016 et al. Apr 10 Online ahead of print
6 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-99
7 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20 105949 et al. Online ahead of print
8 Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L. et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50: 384
9 Moore N. Chloroquine for COVID-19 Infection. Drug Saf 2020; 43: 393-4
10 Wu Y, Wang T, Guo C, Zhang D, Ge X, Huang Z. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. QJM 2020 Apr 10 hcaa121 et al. Online ahead of print
11 Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM. et al. Convalescent plasma: New evidence for an old therapeutic tool?. Blood Trans 2016; 14: 152-7
12 Duan K, Liu B, Li C, Zhang H, Yu T, Qu J. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490-6
13 Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J. et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323: 1582-9
14 Leo L. ICMR Seeks Participation for Trial of Plasma Therapy for Covid-19 Treatment. 2020 https://www.livemint.com/news/india/icmr-seeks-participation-for-trial-of-plama-therapy-for-covid-19-treatment-11586784202205.html Available from: [Last accessed on 2020 Apr 15]
15 Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 06.04.2020; Online ahead of print
16 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13 e200994 et al. Online ahead of print
17 Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395: 683-4
18 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094-9
19 Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E. et al. Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46: 854-87
20 http://HCQ_Recommendation_22March_final_MM_V2.pdf Available from: [Last accessed on 2020 Apr 15]
21 Cansu DÜ, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 2008; 47: 378-9
22 Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 2006; 44: 173-5
23 Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: Key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care 2013; 2: 77-83
24 Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 Mar 9 ciaa237 et al. Online ahead of print
25 Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) - Full Text View - ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT04318444 Available from: [Last accessed on 2020 Apr 15]
26 Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis 17.04.2020; Online ahead of print
27 Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. New England J Med 2020; 382: 1969-73